Video

Reporting from ESMO Congress 2019, Christophe Tournigand comments on results from the subgroup, pooled and cohort analysis in the studies that show improvements in the response rate and overall survival with immune checkpoint inhibitors treatment in patients with Microsatellite Instability (MSI)-high tumours. He emphasizes the importance of MSI testing in patients with gastrointestinal, endometrial and other cancer types.

Major Sponsors

AstraZeneca Bristol-Myers Squibb MSD Servier

Main Sponsors

Bayer Healthcare Boehringer Ingelheim Daiichi Sankyo ipsen Janssen logo Novartis Pfizer Oncology Roche